Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Raw Materials (2016 - 2019)

Plus Therapeutics (PSTV) has disclosed Raw Materials for 9 consecutive years, with $663000.0 as the latest value for Q1 2019.

  • On a quarterly basis, Raw Materials fell 4.6% to $663000.0 in Q1 2019 year-over-year; TTM through Mar 2019 was $663000.0, a 4.6% decrease, with the full-year FY2018 number at $758000.0, up 11.31% from a year prior.
  • Raw Materials was $663000.0 for Q1 2019 at Plus Therapeutics, down from $758000.0 in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $1.7 million in Q1 2015 to a low of $663000.0 in Q1 2019.
  • A 5-year average of $1.0 million and a median of $907000.0 in 2017 define the central range for Raw Materials.
  • Peak YoY movement for Raw Materials: skyrocketed 56.58% in 2017, then tumbled 53.81% in 2018.
  • Plus Therapeutics' Raw Materials stood at $1.0 million in 2015, then fell by 12.29% to $885000.0 in 2016, then decreased by 23.05% to $681000.0 in 2017, then rose by 11.31% to $758000.0 in 2018, then fell by 12.53% to $663000.0 in 2019.
  • Per Business Quant, the three most recent readings for PSTV's Raw Materials are $663000.0 (Q1 2019), $758000.0 (Q4 2018), and $698000.0 (Q3 2018).